Clinical trials: Polyomavirus Infections
Dermatologic Conditions, Healthy Volunteers
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
Background: Skin disease can have many causes. It can have widespread consequences, and in rare cases can lead to death. Researchers want to determine the causes of various types of skin diseases and find a way to treat them.
- Conditions
- Dermatologic Conditions, Healthy Volunteers, Normal Volunteers, Carcinoma, Merkel Cell
- Trial name
- NCT02471352
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT05896839
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Progressive Multifocal Leukoencephalopathy
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
The purpose of this study is to explore host genetic mutations which may render individual subjects more susceptible (or resistant) to developing Progressive Multifocal Leukoencephalopathy (PML).
- Trial name
- NCT01211639
- Where
- 11 sites in United States, Germany
- Volunteers
- 24 people
- Sponsor
- Biogen
Disease Due to BK Polyomavirus, Transplantation Infection
Induction Related BK Viremia in Renal Transplant Patients
The increase immunosuppression in our transplant population has led to an unacceptable rate of patients at risk for BK virus nephropathy.
- Conditions
- Disease Due to BK Polyomavirus, Transplantation Infection, Disorder Related to Transplantation
- Trial name
- BK (NCT00610961)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida
Carcinoma of Unknown Primary, Neuroendocrine Carcinoma
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have advanced…
- Conditions
- Carcinoma of Unknown Primary, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma of the Skin
- Trial name
- NCT00004922
- Testing
- irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Merkel Cell Carcinoma
A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
This is a single arm, open-label, single center study evaluating the safety, feasibility, clinical efficacy and immunogenicity of GLA-SE administration to patients with Merkel cell carcinoma. Ten patients will be treated.
- Trial name
- NCT02035657
- Testing
- GLA-SE
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Advanced Solid Tumors, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC
- Trial name
- NCT04272034
- Testing
- INCB099318
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Incyte Corporation
Advanced Solid Tumors, NSCLC
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have…
- Conditions
- Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC
- Trial name
- NCT04157985
- Testing
- Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Dan Zandberg
Progressive Multifocal Leukoencephalopathy, PML
Observational Study on Characteristics and Survival Correlates of Progressive Multifocal Leukoencephalopathy (PML) in Italy
The goal of this observational study is to learn about the features of Progressive Multifocal Leukoencephalopathy (PML) at the time of its diagnosis and the factors that may influence the outcome of persons with this disease.
- Trial name
- MI_PML (NCT06594614)
- Where
- Italy
- Volunteers
- 456 people
- Sponsor
- Scientific Institute San Raffaele
Metastatic Merkel Cell Carcinoma
Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Expanded access to Avelumab solution for infusion will be made available for adult patients with mMCC whose disease has progressed after receiving at least one prior chemotherapy.
- Trial name
- NCT03089658
- Testing
- Avelumab
- Where
- France
- Sponsor
- Merck KGaA, Darmstadt, Germany
Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
- Conditions
- Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
- Trial name
- NCT05358938
- Testing
- Exercise, Checkpoint Blockade, Immune
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neuroendocrine Tumors, Insulinoma
DOTATOC PET/CT for Imaging NET Patients
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called…
- Conditions
- Neuroendocrine Tumors, Insulinoma, Gastrinoma, Glucagonoma
- Trial name
- NCT03583528
- Testing
- 68Ga-DOTATOC PET/CT, 18F-FDG PET/CT
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- British Columbia Cancer Agency
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Disease Due to BK Polyomavirus, Kidney Transplant Infection
Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study
Primary Research Questions: Efficacy, safety and feasibility of a 3-month course of levofloxacin in a pilot study will be assessed. 1.
- Trial name
- NCT01353339
- Testing
- Levofloxacin
- Where
- 11 sites in Canada
- Volunteers
- 154 people
- Sponsor
- Ottawa Hospital Research Institute
Other Skin
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
This phase I/II trial studies the side effects of gene-modified immune cells (FH-MCVA2TCR) and to see how well they work in treating patients with Merkel cell cancer that has spread to other parts of the body (metastatic) or that…
- Trial name
- NCT03747484
- Testing
- Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Avelumab, Pembrolizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Solid Tumors Cancer
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with ABBV-181 in participants with locally advanced or…
- Trial name
- NCT03071757
- Testing
- ABBV-368, ABBV-181
- Where
- 27 sites in United States, France and 4 more
- Volunteers
- 139 people
- Sponsor
- AbbVie
BK Viremia, Kidney Transplant Infection
A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients
BEAT-BK will see the effect of immunosuppression reduction/modification with and without IVIG on BKPyV infection, allograft function, allograft loss, acute transplant rejection, immunosuppression load and death in kidney and…
- Conditions
- BK Viremia, Kidney Transplant Infection, Kidney Transplant Failure and Rejection
- Trial name
- BEAT-BK (NCT05325008)
- Testing
- Immunosuppression reduction/modification + intravenous immunoglobulin, Immunosuppression reduction/modification
- Where
- 13 sites in Australia
- Volunteers
- 280 people
- Sponsor
- The University of Queensland
Graft Rejection, Kidney Transplantation
Artificial Intelligence Model for Renal Allograft Rejection Identification, Lesion Quantification and Rejection Risk Prediction Based on Prospective Renal Transplant Pathology and Clinical Multidimensional Data
This prospective research collects leftover kidney biopsy tissue slides and matching routine clinical data from patients who received kidney transplants and underwent standard kidney puncture biopsy at Zhejiang University School…
- Conditions
- Graft Rejection, Kidney Transplantation, Glomerulonephritis, Polyomavirus Infections
- Trial name
- NCT07741552
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chen Dajin
Advanced Or Metastatic Merkel Cell Carcinoma
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult participant (≥18 years) with non-cutaneous Merkel Cell Carcinoma.
- Trial name
- NCT06940440
- Testing
- IFx-Hu2.0, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- TuHURA Biosciences, Inc.